SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WWS who wrote (407)9/6/1996 9:32:00 PM
From: Richard Mazzarella   of 4342
 
Bill, thanks for the information. I think that the problem with past studies are the same as your experiment with a cold cure. It's just hit and miss without quantitative analysis. The PRLN methods quantify interactions such that the drugs can be optimized. The signal transduction technology is the reason PRLN has any value as a company. The common cold has some of the elusive properties of HIV (resistance, mutation, etc.. I wouldn't be surprised if PRLN doesn't do something good there, but then I really don't know what I am talking about and am just speculating. It's fun none the less.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News